Default company panoramic image

Chelation Partners

Dramatically enhances antibiotic efficacy by starving pathogens of essential and irreplaceable iron. Supercharges existing antibiotics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Halifax, NS, Canada
  • Currency USD
  • Founded April 2011
  • Employees 5
  • Website

Company Summary

Life threatening infections are developing resistance faster than new antibiotics are discovered and approved costing hundreds of millions of dollars and thousands of lives. Chelation Partners offers a solution to this problem by starving pathogens of iron with a new family of agents improving the efficacy of drugs. These agents are extremely simple to use; just co-administer with an antibiotic. The antibiotic market in 2010 was $50+ billion.


  • Photo
    Co-Founder VP Business Development

    An experienced life-sciences executive, with formal training in genetics. Involved with multiple start-up companies. Successful exits as well as guided development as well as commercialization of numerous technologies. Extensive Business Development, deal brokering, licensing and financing experience.

  • Default avatar
    Natasha Sideris
    Chief Financial Officer

    Extensive experience with start-up companies as well as large corporate firms.

  • F1563744 2f1d 44c5 a9cb 5ca7f41ecbcb
    Co-Founder, President

    Bruce E. Holbein, Ph.D. in microbiology with over 25 years experience in research and commercial technology development. Bruce is a principal of Chelation Partners and inventor of the CP™ Technology. He has managed the development and commercialization of environmental and microbial biotechnologies, is inventor on 12 patents.

Previous Investors